Lates News

Chi Fei Biotech announced that the company signed a revised and restated supply, distribution, and co-promotion agreement with MSD on April 2, 2026. The original agreement will terminate upon the effectiveness of the new agreement. The new agreement aims to deepen the strategic cooperation between the two parties, enhance market synergy, address operational pressures, and includes products such as the nine-valent HPV vaccine. The cooperation period extends until the end of 2028 and may be extended for two years. The company will adjust procurement and supply quantities dynamically based on market demand, and performance under the agreement will be disclosed regularly. The new agreement no longer specifies a base purchase amount for the agreement products. Chi Fei Biotech and MSD will negotiate and confirm expected procurement and supply plans based on market expectations and actual vaccination situations. The company will then procure the agreement products on a rolling basis. Specific procurement details will be based on orders confirmed in writing by both parties.